-
TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade
Saturday, June 2, 2018 - 4:16pm | 477Read More...TapImmune, Inc. (NASDAQ: TPIV) will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note. The Analyst WBB Securities analyst Steve Brozak upgraded TapImmune from a Speculative Buy...
-
Could ViroPharma Benefit from Multiple Generic Versions of VANCOCIN?
Wednesday, April 11, 2012 - 12:28pm | 374Read More...Yesterday morning, the US Food and Drug Administration approved three drug manufacturers' generic versions of ViroPharma's (NASDAQ: VPHM) VANCOCIN HCl capsules. According to Watson Pharmaceuticals' (NYSE: WPI) statment, VANCOCIN is indicated for the treatment of C. difficile-associated diarrhea and...
